NCT01707472已完成2 期
A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Percentage of Participants Experiencing Treatment-Emergent Adverse Events
研究概览
简要总结
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-infected individuals must have positive serologies with viral load suppressed below 400 copies/mL
- •HCV-infected individuals must have:
- •Chronic HCV infection with HCV RNA ≥ 2000 IU/ml AND at least 1 of the following:
- •Been null responder to previous pegylated interferon and ribavirin therapy OR
- •Failed to achieve sustained virologic response (SVR) on a regimen containing a direct-acting antiviral (DAA) in addition to pegylated interferon and ribavirin OR
- •Are unwilling to receive or have contraindications to interferon therapy for HCV
- •HIV/HCV co-infected individuals must have:
- •Positive HIV serologies with viral load suppressed below 400 copies/mL
- •Chronic HCV infection with HCV RNA ≥ 2000 IU/ml AND at least 1 of the following:
- •Been null responder to previous pegylated interferon and ribavirin therapy OR
- •Failed to achieve SVR on a regimen containing a direct-acting antiviral (DAA) in addition to pegylated interferon and ribavirin OR
- •Are unwilling to receive or have contraindications to interferon therapy for HCV
- •Willing to allow blood and tissue samples to be stored for future use to study HIV infection, immune function, liver disease and additional mechanisms involved in liver fibrosis among patients with HIV and/or HCV, which may not be related directly to the specific objectives of this study protocol
- •Have a primary care physician
排除标准
- •Cause of liver fibrosis other than HCV or long-term antiretroviral therapy (ART) treatment for HIV
- •Currently being treated for HCV
- •Evidence of active Hepatitis A, B or D infections
- •History or evidence of hepatocellular carcinoma
- •Unwillingness to undergo a liver biopsy pre-treatment and post-treatment, or to undergo all other protocol required tests/procedures or return to the site for required visits
- •Presence of contraindications to magnetic resonance imaging (e.g., presence of any metal in the body, cardiac or neural pacemaker, aneurysm clip, cochlear implant, claustrophobia)
结局指标
主要结局
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
时间窗: First dose date up to Week 24 plus 30 days
次要结局
- Change From Baseline in Alpha SMA at Week 24(Baseline; Week 24)
- Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24(Baseline; Week 24)
- Change From Baseline in HVPG at Week 24(Baseline; Week 24)
- Change From Baseline in MQC at Week 24(Baseline; Week 24)
- Change From Baseline in Liver Fibrosis as Estimated by MRE at Week 24(Baseline; Week 24)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
2 期
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent GlioblastomaRecurrent GlioblastomaNCT05540275Henan Provincial People's Hospital30
终止
2 期
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisNCT01769196Gilead Sciences544
终止
2 期
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman DiseaseIdiopathic Multicentric Castleman's DiseaseNCT04838860EusaPharma (UK) Limited22
终止
2 期
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's SyndromeSjögren's SyndromeNCT02843659Bristol-Myers Squibb45
已完成
2 期
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma RefractoryDiffuse Large B-cell Lymphoma RecurrentNCT03589469ADC Therapeutics S.A.145